Free Download Brochure for

SmartPRep2 – APC and BMAC

More Downloads

Key Technology Partner

TriCell associated with Harvest Technologies, a world leader in developing technologies that accelerate natural healing, to bring-in a next generation technology Bone Marrow Aspirate Concentrate (BMAC) system in India. BMAC is a USFDA and CE approved biological technology that accelerates the body’s natural healing capacity, thereby improving surgical outcomes.

Talking on the association with Harvest Technologies, Mr. Mayur Abhaya, Executive Director, TriCell says, “We are excited to partner with Harvest Technologies to bring-in international standards to India. TriCell is today India’s only comprehensive stem cells solutions provider as we offer a complete spectrum of services and with this association we intend to accelerate the availability of advanced stem cell therapy in India.

According to Scott Shea, Managing Director, Harvests Technologies GmbH, “The Autologous regenerative cells from bone marrow offer profound potential for therapies. Harvest has conducted about 30,000 clinical procedures for various applications, the highest number of procedures in the world, using the BMAC System. Our novel technology now makes it possible to harvest the regenerative cells safely and rapidly in order to develop new therapies for heretofore incurable diseases”.

“We are delighted to be associated with TriCell, an undisputed market leader in stem cell technology space and extend our services in India. It has a well established network with hospitals and clinical institutions across India and we would leverage their strength to rapidly deploy our service across the country and provide HOPE in addressing unmet medical challenges by offering cellular therapeutic options”.

About Harvest® Technologies’ breakthrough BMAC™ (Bone Marrow Aspirate Concentrate) System:

Harvest Technologies has decades of cumulative experience designing, manufacturing and marketing devices for blood component separation, platelet sequestration, and bone marrow derived stem cell harvesting. Harvest® has received clearance in Europe to concentrate the cellular components from bone marrow via its breakthrough BMAC™ (Bone Marrow Aspirate Concentrate) System, currently being used in Europe to treat vascular, orthopedic and cardiovascular diseases. The BMAC System helps in safe and rapid preparation of cell concentrate from bone marrow. Existing methods to produce a stem cell concentrate therapy are time consuming, labour intensive, and require complex logistical considerations. BMAC is the first and only product that makes possible the use of a clinically effective quantity of cellular compositions from a small aspirate of autologous bone marrow, which includes a large quantity of adult stem cells, derived from a patient at point-of care in just 15 minutes.